Aptorum Group Limited (APM) announced a definitive agreement for an all-stock merger, where DiamiR Biosciences will retain its name and become a wholly-owned subsidiary of Aptorum Group upon completion.
Both companies’ boards of directors have approved the merger, which is expected to close in the fourth quarter of 2025. Aptorum Group Limited will seek shareholder approval for share issuance related to the merger, as well as proposals on Domestication and a reverse stock split, to be presented at the upcoming meeting.
Ian Huen, CEO and Chairman of Aptorum Pharmaceuticals, stated that the combined company aims to become a global life sciences leader, generating revenue through biopharma services and providing essential biomarker panels for complex-biology indications to better characterize patients.
